1. Home
  2. JYNT vs GNLX Comparison

JYNT vs GNLX Comparison

Compare JYNT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.91

Market Cap

118.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.86

Market Cap

133.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYNT
GNLX
Founded
2010
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.2M
133.0M
IPO Year
2014
2022

Fundamental Metrics

Financial Performance
Metric
JYNT
GNLX
Price
$8.91
$2.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$17.00
$17.25
AVG Volume (30 Days)
164.8K
199.2K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
133.93
9.47
EPS
0.09
N/A
Revenue
$117,696,356.00
$8,000.00
Revenue This Year
$12.23
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$100.78
N/A
Revenue Growth
15.49
N/A
52 Week Low
$7.50
$2.29
52 Week High
$11.78
$8.54

Technical Indicators

Market Signals
Indicator
JYNT
GNLX
Relative Strength Index (RSI) 48.73 45.57
Support Level $8.04 $2.73
Resistance Level $9.53 $3.00
Average True Range (ATR) 0.43 0.15
MACD -0.01 -0.01
Stochastic Oscillator 50.41 15.79

Price Performance

Historical Comparison
JYNT
GNLX

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: